<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00298610</url>
  </required_header>
  <id_info>
    <org_study_id>WRAIR 1168</org_study_id>
    <secondary_id>KEMRI 917</secondary_id>
    <secondary_id>HSRRB A-13331</secondary_id>
    <nct_id>NCT00298610</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of IV Artesunate to Treat Malaria</brief_title>
  <official_title>A Phase II, Open Label, Study of the Safety, Tolerability, Efficacy and Pharmacokinetics of Intravenous Artesunate in Adults With Uncomplicated Malaria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>U.S. Army Medical Research and Materiel Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Military Infectious Diseases Research Program (MIDRP)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>U.S. Army Medical Research and Materiel Command</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine how GMP IV Artesunate is metabolized and cleared by
      individuals with uncomplicated malaria infection and to determine how fast it eliminates
      malaria infection from the body.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an unblinded non-randomized phase II pharmacokinetic study of a new GMP formulation
      of intravenous artesunate. Artesunate has been used throughout Asia and Africa for many
      years. Its overall efficacy associated with the ability to lower parasitemia is well
      established. To date, pharmacokinetic studies have not been done in Africa using GMP (Good
      Manufacturing Practices)-produced drug. The objective of this study is to show that GMP IV
      artesunate rapidly clears parasites in Adult Kenyan populations with malaria and that the
      pharmacokinetic profile of the drug approximates other populations of adults tested (Asians
      and North Americans).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Percentage of Parasites Detected at 48 Hours</measure>
    <time_frame>48 hours</time_frame>
    <description>Change in Percentage of Parasites Detected at 48 Hours. With positive numbers to represent increases and negative numbers to represent decreases</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Parasite Clearance</measure>
    <time_frame>24 and 48 hours post dose</time_frame>
    <description>The target variable is detection (percentage) of asexual stage parasites of Plasmodium falciparum malaria in bloodstream by Giemsa - stained microscopy of thick and thin blood smears</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Fever Clearance</measure>
    <time_frame>Within 48 hours post dose</time_frame>
    <description>Temperature is measured by oral digital thermometers, and fever clearance time is defined as the first time with resolution of fever (&lt;37.5C) sustained for 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Severity of Adverse Events</measure>
    <time_frame>up to 14 days</time_frame>
    <description>Determine the safety (defined as severity of AE's using the Common Toxicity Criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Adverse Events Relationship to Study Drug</measure>
    <time_frame>up to 14 days</time_frame>
    <description>Determine the safety (defined as relationship to study drug of AE's and SAE's)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Severity of Serious Adverse Events (SAE's)</measure>
    <time_frame>up to 14 days</time_frame>
    <description>Determine the safety (defined as severity of SAE's using the Common Toxicity Criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Serious Adverse Event (SAE) Relationship to Study Drug</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Determine the safety (defined as relationship to study drug of SAE's)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Artesunate and Malarone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject are given intravenous Artesunate once a day for 3 days. Following completion of Artesunate treatment, all subjects received Malarone follow-on therapy to ensure parasitologic cure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artesunate and Malarone</intervention_name>
    <description>Intravenous Artesunate (2.4 mg/kg) once a day for three days and Malarone (proguanil/atovaquone) follow-on therapy (4 tablets once daily for three days)</description>
    <arm_group_label>Artesunate and Malarone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult male &amp; non-pregnant females, 18-65 years

          -  Fever, defined as &gt;37.5ÂºC, during the current illness, or history (within the last 48
             hours) of fever.

          -  Diagnosis of falciparum malaria, greater than or equal to 200 parasites/uL

          -  Able to communicate well with the investigator and to comply with the requirements of
             the entire study.

          -  Willing to be admitted for the period of drug administration and/or to follow up
             (return to hospital)

          -  Provision of the written informed consent to participate as shown by a signature on
             the informed consent form.

        Exclusion Criteria:

          -  Administration of any investigational drug in the period 0 to 16 weeks before entry to
             the study.

          -  The use of any medication during the period 0 to 14 days (prescribed drugs) or 0 to 5
             days (OTC) before entry to the study (including herbal or dietary supplements), except
             those deemed by the principal investigator / clinical investigator not to interfere
             with the outcome of the study.

          -  Existence of any surgical or medical condition that, in the judgment of the clinical
             investigator, might interfere with the distribution, metabolism or excretion of the
             drug.

          -  History of serious adverse reaction or hypersensitivity to study drug or follow on
             treatment.

          -  Mixed malaria infection (malaria other than falciparum malaria mono-infection as
             detected by screening blood smear)

          -  Severe falciparum malaria (as defined by the WHO; Attachment 1).

          -  Donation or loss of greater than 400 ml of blood in the period 0 to 12 weeks before
             entry to the study,

          -  Transfusion of blood within past 30 days.

          -  Refusal to prevent pregnancy during the 14 days of the trial

          -  Pregnancy as defined clinically or by a positive urine BHCG at the time of screening,
             or nursing mothers.

          -  Laboratory evidence or history of significant cardiovascular, liver or renal
             functional abnormality, which in the opinion of the investigator would place them at
             increased risk. Specifically, the following will serve as exclusionary lab values:

               -  Creatinine &gt;1.4 x ULN (&gt;2.0 mg/dL)

               -  Glucose &lt;LLN (65mg/dL)

               -  AST, ALT &gt;3x ULN (120 U/L)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shon A Remich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Walter Reed Army Institute of Research (WRAIR)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New Nyanza Provincial Hospital</name>
      <address>
        <city>Kisumu</city>
        <state>New Nyanza</state>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kenya</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2006</study_first_submitted>
  <study_first_submitted_qc>March 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2006</study_first_posted>
  <results_first_submitted>November 30, 2016</results_first_submitted>
  <results_first_submitted_qc>February 1, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 22, 2017</results_first_posted>
  <last_update_submitted>February 1, 2017</last_update_submitted>
  <last_update_submitted_qc>February 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Uncomplicated Malaria</keyword>
  <keyword>GMP artesunate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Artesunate</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
    <mesh_term>Atovaquone, proguanil drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Thirty adult subjects with uncomplicated malaria were recruited from the endemic malarious region of Nyanza province in Kenya came to the New Nyanza Medical Center or sub-location recruitment sites.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Artesunate and Malarone</title>
          <description>Subject are given intravenous Artesunate once a day for 3 days. Following completion of Artesunate treatment, all subjects received Malarone follow-on therapy to ensure parasitologic cure.
Artesunate and Malarone: Intravenous Artesunate (2.4 mg/kg) once a day for three days and Malarone (proguanil/atovaquone) follow-on therapy (4 tablets once daily for three days)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Artesunate and Malarone</title>
          <description>Subject are given intravenous Artesunate once a day for 3 days. Following completion of Artesunate treatment, all subjects received Malarone follow-on therapy to ensure parasitologic cure.
Artesunate and Malarone: Intravenous Artesunate (2.4 mg/kg) once a day for three days and Malarone (proguanil/atovaquone) follow-on therapy (4 tablets once daily for three days)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Tribe = Luo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tribe = Luyha</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tribe = Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Kenya</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Percentage of Parasites Detected at 48 Hours</title>
        <description>Change in Percentage of Parasites Detected at 48 Hours. With positive numbers to represent increases and negative numbers to represent decreases</description>
        <time_frame>48 hours</time_frame>
        <population>Percentage of parasite change at 48 hours post dose</population>
        <group_list>
          <group group_id="O1">
            <title>Artesunate and Malarone</title>
            <description>Subject are given intravenous Artesunate once a day for 3 days. Following completion of Artesunate treatment, all subjects received Malarone follow-on therapy to ensure parasitologic cure.
Artesunate and Malarone: Intravenous Artesunate (2.4 mg/kg) once a day for three days and Malarone (proguanil/atovaquone) follow-on therapy (4 tablets once daily for three days)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percentage of Parasites Detected at 48 Hours</title>
          <description>Change in Percentage of Parasites Detected at 48 Hours. With positive numbers to represent increases and negative numbers to represent decreases</description>
          <population>Percentage of parasite change at 48 hours post dose</population>
          <units>percentage of parasite change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.998" spread="0.0006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Parasite Clearance</title>
        <description>The target variable is detection (percentage) of asexual stage parasites of Plasmodium falciparum malaria in bloodstream by Giemsa - stained microscopy of thick and thin blood smears</description>
        <time_frame>24 and 48 hours post dose</time_frame>
        <population>Percentage of parasite clearance within the first 24 and 48 hours post dose of intravenous artesunate</population>
        <group_list>
          <group group_id="O1">
            <title>Artesunate and Malarone</title>
            <description>Subject are given intravenous Artesunate once a day for 3 days. Following completion of Artesunate treatment, all subjects received Malarone follow-on therapy to ensure parasitologic cure.
Artesunate and Malarone: Intravenous Artesunate (2.4 mg/kg) once a day for three days and Malarone (proguanil/atovaquone) follow-on therapy (4 tablets once daily for three days)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Parasite Clearance</title>
          <description>The target variable is detection (percentage) of asexual stage parasites of Plasmodium falciparum malaria in bloodstream by Giemsa - stained microscopy of thick and thin blood smears</description>
          <population>Percentage of parasite clearance within the first 24 and 48 hours post dose of intravenous artesunate</population>
          <units>percentage of parasite clearance</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.421" spread="1.365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.998" spread="0.0006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Fever Clearance</title>
        <description>Temperature is measured by oral digital thermometers, and fever clearance time is defined as the first time with resolution of fever (&lt;37.5C) sustained for 24 hours</description>
        <time_frame>Within 48 hours post dose</time_frame>
        <population>Summary of subject with fever clearance, defined as first sustained absence of fever (&lt;37.5C for least 24 hours)</population>
        <group_list>
          <group group_id="O1">
            <title>Artesunate and Malarone</title>
            <description>Subject are given intravenous Artesunate once a day for 3 days. Following completion of Artesunate treatment, all subjects received Malarone follow-on therapy to ensure parasitologic cure.
Artesunate and Malarone: Intravenous Artesunate (2.4 mg/kg) once a day for three days and Malarone (proguanil/atovaquone) follow-on therapy (4 tablets once daily for three days)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Fever Clearance</title>
          <description>Temperature is measured by oral digital thermometers, and fever clearance time is defined as the first time with resolution of fever (&lt;37.5C) sustained for 24 hours</description>
          <population>Summary of subject with fever clearance, defined as first sustained absence of fever (&lt;37.5C for least 24 hours)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety - Severity of Adverse Events</title>
        <description>Determine the safety (defined as severity of AE's using the Common Toxicity Criteria)</description>
        <time_frame>up to 14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Artesunate and Malarone</title>
            <description>Subject are given intravenous Artesunate once a day for 3 days. Following completion of Artesunate treatment, all subjects received Malarone follow-on therapy to ensure parasitologic cure.
Artesunate and Malarone: Intravenous Artesunate (2.4 mg/kg) once a day for three days and Malarone (proguanil/atovaquone) follow-on therapy (4 tablets once daily for three days)</description>
          </group>
        </group_list>
        <measure>
          <title>Safety - Severity of Adverse Events</title>
          <description>Determine the safety (defined as severity of AE's using the Common Toxicity Criteria)</description>
          <units>Number of adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety - Adverse Events Relationship to Study Drug</title>
        <description>Determine the safety (defined as relationship to study drug of AE's and SAE's)</description>
        <time_frame>up to 14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Artesunate and Malarone</title>
            <description>Subject are given intravenous Artesunate once a day for 3 days. Following completion of Artesunate treatment, all subjects received Malarone follow-on therapy to ensure parasitologic cure.
Artesunate and Malarone: Intravenous Artesunate (2.4 mg/kg) once a day for three days and Malarone (proguanil/atovaquone) follow-on therapy (4 tablets once daily for three days)</description>
          </group>
        </group_list>
        <measure>
          <title>Safety - Adverse Events Relationship to Study Drug</title>
          <description>Determine the safety (defined as relationship to study drug of AE's and SAE's)</description>
          <units>Number of adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None or remote</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Possible, probable, definate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety - Severity of Serious Adverse Events (SAE's)</title>
        <description>Determine the safety (defined as severity of SAE's using the Common Toxicity Criteria)</description>
        <time_frame>up to 14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Artesunate and Malarone</title>
            <description>Subject are given intravenous Artesunate once a day for 3 days. Following completion of Artesunate treatment, all subjects received Malarone follow-on therapy to ensure parasitologic cure.
Artesunate and Malarone: Intravenous Artesunate (2.4 mg/kg) once a day for three days and Malarone (proguanil/atovaquone) follow-on therapy (4 tablets once daily for three days)</description>
          </group>
        </group_list>
        <measure>
          <title>Safety - Severity of Serious Adverse Events (SAE's)</title>
          <description>Determine the safety (defined as severity of SAE's using the Common Toxicity Criteria)</description>
          <units>Number of events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety - Serious Adverse Event (SAE) Relationship to Study Drug</title>
        <description>Determine the safety (defined as relationship to study drug of SAE's)</description>
        <time_frame>Up to 14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Artesunate and Malarone</title>
            <description>Subject are given intravenous Artesunate once a day for 3 days. Following completion of Artesunate treatment, all subjects received Malarone follow-on therapy to ensure parasitologic cure.
Artesunate and Malarone: Intravenous Artesunate (2.4 mg/kg) once a day for three days and Malarone (proguanil/atovaquone) follow-on therapy (4 tablets once daily for three days)</description>
          </group>
        </group_list>
        <measure>
          <title>Safety - Serious Adverse Event (SAE) Relationship to Study Drug</title>
          <description>Determine the safety (defined as relationship to study drug of SAE's)</description>
          <units>Number of events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None or Remote</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Possible, Probable, Definate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>14 Days</time_frame>
      <desc>AE's were solicited using standardized questionnaires at each clinic visit (Days 0 - 14+2)</desc>
      <group_list>
        <group group_id="E1">
          <title>Artesunate and Malarone</title>
          <description>Subject are given intravenous Artesunate once a day for 3 days. Following completion of Artesunate treatment, all subjects received Malarone follow-on therapy to ensure parasitologic cure.
Artesunate and Malarone: Intravenous Artesunate (2.4 mg/kg) once a day for three days and Malarone (proguanil/atovaquone) follow-on therapy (4 tablets once daily for three days)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Stevens-Johnson Syndrome</sub_title>
                <description>Possibly related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Abdominal pain, upper</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Abdominal pain, upper</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Infusion site pain</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Infusion site pain</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Viraemia</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Viraemia</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Bilirubin decreased</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Bilirubin decreased</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Tachypoea</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Tachypnoea</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Stevens-Johnson syndrome</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Stevens-Johnson syndrome</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Shon A. Remich, MD</name_or_title>
      <organization>Walter Reed Army Institute of Research</organization>
      <phone>254-733-628-670</phone>
      <email>sremich@hotmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

